Clinical trial Recruiting at 1 site Observational Ages 29 Days to 28

Comparing AN69ST and PS membranes for blood purification in children with sepsis

Official title: The Effects of a AN69ST Membrane and Polysulphone Membrane on Septic Children With Continuous Blood Purification

Run by Children's Hospital of Fudan University · NCT05692011 · Data updated 2026-11-12

This compares AN69ST and PS membranes during blood purification to see if one helps children with sepsis recover better.

More Sepsis trials

Quick facts

Study typeObservational
Ages29 Days to 28 Years
SexAll
Enrollment80 (estimated)
SponsorChildren's Hospital of Fudan University
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 17, 2026
Trial IDNCT05692011 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 29 days to 18 years with sepsis causing dysfunction of more than one organ or septic shock diagnosed within 48 hours and who are eligible for blood purification are ideal candidates.

Probably not a fit

Patients unlikely to benefit include those on chronic dialysis for end-stage renal disease, with non-septic shock, uncontrolled hemorrhage, severe immunodeficiency, recent chemoradiotherapy or immunosuppression, extensive recent burns, heparin allergy, or those unable to consent or present more than 48 hours after diagnosis.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective cohort study comparing two blood purification membrane types (AN69ST versus PS) in children with sepsis who require continuous blood purification. Eligible patients are aged 29 days to 18 years with sepsis-induced multi-organ dysfunction or septic shock diagnosed within 48 hours. The study will follow clinical outcomes and inflammatory markers to compare efficacy and prognosis between the two membrane groups. Because randomized pediatric trials are scarce, this observational approach aims to generate evidence to guide membrane choice in pediatric critical care.

Why it matters

Potential benefit: If successful, the results could identify which membrane better reduces inflammation and improves recovery and prognosis in children receiving blood purification for sepsis.

How similar studies have gone: Adult studies and some pediatric observational reports suggest blood purification can lower cytokines and improve hemodynamics, but randomized data in children comparing membrane types are very limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Meet the 2005 diagnostic criteria for sepsis
* Age 29 days - 18 years old
* Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock
* Diagnosis \< 48 hours

Exclusion Criteria:

* Inability to obtain an informed consent from the subject, family member or an authorized surrogate
* Subject has end-stage renal disease and requires chronic dialysis
* There is clinical support for non-septic shock
* Subject has had chest compressions as part of cardiopulmonary resuscitation this hospitalization without immediate return to communicative state
* Subject has uncontrolled hemorrhage
* Subject has immunodeficiency diseases
* Subject has received chemoradiotherapy or immunosuppressive therapy in the 14 days before enrollment
* HIV infection in association with a last known or suspected CD4 count of \<50/mm3
* Subject has sustained extensive third-degree burns within the past 7 days
* Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia
* Subject is currently enrolled in an investigational drug or device trial
* Subject has been previously enrolled in the current trial
* Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end stage chronic illness with no reasonable expectation of survival to hospital discharge
* Known hypersensitivity to hemofilter
* Subject has received organ transplantation
* Subject is expected to die within 24 hours

Where it's running

  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.